Evidence for a role of phospholipid oxidation products in atherogenesis

Trends in Cardiovascular Medicine

Volumn 11, Issue 3-4, 2001, Pages 142-147

  Berliner, Judith A ^a,c   Subbanagounder, Ganesamoorthy ^a   Leitinger, Norbert ^a,b   Watson, Andrew D ^a   Vora, Devendra ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; FATTY ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYSINE DERIVATIVE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; THROMBOCYTE ACTIVATING FACTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CELL ACTIVATION; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CHRONIC DISEASE; DISEASE COURSE; ENZYME ACTIVATION; GENETIC POLYMORPHISM; HUMAN; HYDROLYSIS; IN VITRO STUDY; LIPID OXIDATION; LIPID STORAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035190081     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(01)00098-6     Document Type: Review

References (60)

1. Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization
2. Mildly oxidized LDL induces expression of group IIa secretory phospholipase A(2) in human monocyte-derived macrophages
3. Oxidized lipids in atherogenesis: Formation, destruction and action
4. Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity
5. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein
6. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant
7. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner
8. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells
9. Tissue factor expression of human monocytes is suppressed by lysophosphatidylcholine
10. Random versus selective membrane phospholipid oxidation in apoptosis: Role of phosphatidylserine
11. Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes
12. Modification of the Recalde method for the isolation of human monocytes
13. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells
14. Structural differences in the ability of lysophospholipids to inhibit endothelium-dependent hyperpolarization by acetylcholine in rat mesenteric arteries
15. Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions
16. Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation
17. Oxidized LDL modulates activation of NFkappaB in mononuclear phagocytes by altering the degradation of IkappaBs
18. Characterization and change of phospholipids in the aorta of Watanabe hereditable hyperlipidemic rabbit
19. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells
20. Induction of monocyte binding to endothelial cells by MM-LDL: Role of lipoxygenase metabolites
21. Oxidized phospholipids as a new landmark in atherosclerosis
22. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein
23. Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulation
24. Involvement of phospholipids in apolipoprotein B modification during low density lipoprotein oxidation
25. Detection of oxidized phospholipid-protein adducts using anti-15-hydroperoxyeicosatetraenoic acid-modified protein antibody: Contribution of esterified fatty acid-protein adduct to oxidative modification of LDL
26. Stimulation of monocytes and platelets by short-chain phosphatidylcholines with and without terminal carboxyl group
27. Oxidized LDL and expression of monocyte adhesion molecules
28. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration
29. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells
30. Oxidized phospholipids activate PPAR-alpha and induce endothelial synthesis of monocyte activators
31. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils
32. Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface
33. Paraoxonase and coronary heart disease
34. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity
35. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta
36. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines
37. Biologically active oxidized phospholipids
38. Comparison of formation of D2/E2-isoprostanes and F2-isoprostanes in vitro and in vivo: Effects of oxygen tension and glutathione
39. The isoprostanes. Current knowledge and directions for future research
40. Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway
41. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate
42. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients
43. Novel leukocyte agonists are released by endothelial cells exposed to peroxide
44. Localization of distinct F2-isoprostanes in human atherosclerotic lesions
45. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase
46. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction
47. Protein adducts of iso[4]levuglandin E2, a product of the isoprostane pathway, in oxidized low density lipoprotein
48. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
49. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
50. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions
51. Platelet-activating factor acetylhydrolases
52. Determinants of the bioactivity of oxidized phospholipids: Specific oxidized fatty acyl groups at the sn-2 position
53. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: In vitro and in vivo inhibition by WEB 2086
54. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta
55. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo
56. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein
57. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population
58. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages
59. The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenylyl cyclase